Is phosphodiesterase inhibition a relevant bronchospasmolytic principle?
Kilian
U
U
Department of Pharmacology, Byk Gulden Pharmaceuticals, Konstanz.
Beume
R
R
Eltze
M
M
Schudt
C
C
D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010276:Parasympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors